Industry: Biotechnology (See others in industry)
Address:Date | FilingType | Incremental Cash | Link to Raw Filing | |||
---|---|---|---|---|---|---|
2025-01-31 | New | $3,275,000 | $3,275,000 | Equity Only | 06b | SEC link |
2024-07-24 | Amended | $15,875,000 | $13,250,000 | Debt Only | 06b | SEC link |
2022-10-20 | New | $2,625,000 | $2,625,000 | Debt Only | 06b | SEC link |
2022-03-04 | New | $37,731,621 | $37,731,621 | Equity Only | 06b | SEC link |
2021-07-07 | New | $5,520,000 | Unknown | Debt Only | SEC link | |
2020-09-28 | Amended | $3,250,000 | $500,000 | Equity Only | 06b | SEC link |
2020-05-13 | New | $2,750,000 | $2,750,000 | Equity Only | 06b | SEC link |
Name | Role |
---|---|
Mark Bamforth | Director |
George Fotiades | Director |
Mark Gilbert | Director |
Matthew Haines | Executive |
Derek Hennecke | Director |
Sumiti Jain | Executive |
David Michael Johnston | Director |
Jason Lawrence | Executive |
Abraham S. Maingi | Executive |
Shailesh Maingi | Director |
Michael Nicholson | Executive |
Matthias Schroff | Director, Executive |
Elizabeth Smith | Director |